Search Within

Bone Marrow Transplant

Formats
  1. Meeting Abstract (1531)
  2. Journal Article (1197)
  3. Review (75)
  4. Research Letter (49)
  5. Book Section (34)
  6. Guidelines (26)
  7. Editorial (24)
  8. Correspondence (18)
  9. Conference Paper (14)
  10. Book Whole (1)
  11. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (2970)
  2. Department of Medicine (2970)
  3. Hematologic Malignancies, Division of (2847)
  4. Survivorship Research (1388)
  5. GSK Faculty (931)
  6. CTCR Scholars (873)

More Groups

People
  1. Sergio Giralt (1068)
  2. Miguel-Angel Perales (943)
  3. Sean Devlin (470)
  4. Ann Jakubowski (459)
  5. Gunjan Shah (446)
  6. Heather Landau (435)

More People

Years
  1. 2025 (67)
  2. 2024 (212)
  3. 2023 (263)
  4. 2022 (201)
  5. 2021 (177)
  6. 2020 (208)

More Years

Publications
  1. Blood (887)
  2. Biology of Blood and Marrow Transplantation (516)
  3. Bone Marrow Transplantation (175)
  4. Journal of Clinical Oncology (127)
  5. Transplantation and Cellular Therapy (113)
  6. Blood Advances (94)

More Publications

Publishers
  1. American Society of Hematology (988)
  2. Elsevier Inc. (767)
  3. Nature Publishing Group (261)
  4. American Society of Clinical Oncology (130)
  5. Wiley Blackwell (66)
  6. Taylor & Francis Group (65)

More Publishers

Results (2970)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)
    Meeting Abstract

    Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant
    Meeting Abstract

    Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
    Blood (2022)

    Fulltext@MSK | Save
  • Maintenance Therapy Cessation for Sustained MRD Negative Multiple Myeloma Patients
    Meeting Abstract

    Korde, N.; Diamond, B.; Burge, M.; Hassoun, H.; Landau, H.; Hultcrantz, M.; Mailankody, S.; Maclachlan, K. H.; Shah, U. A.; Derkach, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Nath, K.; Lee, J.; Elko, T. A.; Levy, L.; Preston, E.; Devlin, S. M.; Ponce, D. M.; Lin, R. J.; Shaffer, B. C.; Cho, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Hospital costs and healthcare resource utilization (HRU) for chimeric antigen (CAR) T-cell therapy and stem cell transplant (SCT) in patients with large B-cell lymphoma (LBCL) in the United States (US)
    Meeting Abstract

    Cui, C.; Feng, C.; Rosenthal, N.; Wade, S. W.; Curry, L.; Fu, C.; Shah, G. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
    Meeting Abstract

    Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Multicenter phase I study of post-transplant low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
    Meeting Abstract

    Metheny, L.; Sobecks, R. M.; Cho, C.; Wang, J.; Ciarrone, L.; Caimi, P. F.; Otegbeye, F.; Cooper, B. W.; Gallogly, M.; Malek, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma
    Meeting Abstract

    Tan, C.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Patel, D.; Maclachlan, K. H.; Lahoud, O. B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry
    Meeting Abstract

    Landsburg, D. J.; Frigault, M.; Heim, M.; Foley, S. R.; Hill, B. T.; Ho, C. M.; Jacobson, C. A.; Jaglowski, S.; Locke, F. L.; Ram, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetic model identifies an optimal fludarabine exposure for improved outcomes after CD19-directed CAR T cell therapy for aggressive B-NHL: Analysis from the Cell Therapy Consortium
    Meeting Abstract

    Scordo, M.; Flynn, J. R.; Devlin, S. M.; Gonen, M.; Parascondola, A.; Tomas, A. A.; Shouval, R.; Brower, J.; Porter, D. L.; Schuster, S. J.; more...
    Blood (2022)

    Fulltext@MSK | Save